Recurrence of ROP by 55 weeks' PMA · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy combined with… may leads to lower recurrence of ROP by 55 weeks' postmenstrual age compared with laser/cryotherapy (low certainty).
1 finding from 1 review
Structural outcome ‐ complete retinal detachment (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes structural outcome ‐ complete retinal detachment (unit of analysis:… compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Refractive error ‐ very high myopia ‐ at 30 months of age (unit of analysis: eyes) · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy may leads to lower refractive error ‐ very high myopia ‐ at 30 months of age (unit of… compared with conventional laser/cryotherapy (low certainty).
1 finding from 1 review
Mortality before hospital discharge · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy showed no clear difference in mortality before discharge from primary hospital compared with conventional laser/cryotherapy (low certainty).
1 finding from 1 review
Mortality at 30 months of age · preterm infants with type 1 ROP
Anti‐vascular endothelial growth factor therapy showed no clear difference in mortality at 30 months of age compared with conventional laser/cryotherapy (low certainty).
1 finding from 1 review
Local adverse effects ‐ corneal opacity requiring corneal transplant (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes local adverse effects ‐ corneal opacity requiring corneal transplant… compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Local adverse effects ‐ lens opacity requiring cataract removal (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes local adverse effects ‐ lens opacity requiring cataract removal… compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Recurrence of ROP (up to 6 months of age) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes recurrence of ROP (up to 6 months of age) compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Recurrence of ROP (unit of analysis: eyes) · preterm infants with type 1 ROP
It is very uncertain whether anti‐vascular endothelial growth factor therapy changes recurrence of ROP (unit of analysis: eyes) compared with conventional laser/cryotherapy (very low certainty).
1 finding from 1 review
Mortality (calculated instead of overall survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in mortality (instead of overall survival) compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Quality of life · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality, relapse and progresses (instead of disease‐ or relapse‐free survival) · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in mortality, relapse and progresses (instead of disease‐ or… compared with chemotherapy only (moderate certainty).
1 finding from 1 review
On‐study mortality · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in on‐study mortality compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Severe adverse effects (grade 3+): Infection · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
ATRA in addition to chemotherapy showed no clear difference in infection grade III/IV compared with chemotherapy only (moderate certainty).
1 finding from 1 review
Grade 3 to 4 diarrhoea · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes diarrhoea grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review
Toxicity: grade 3 or 4 nausea ± vomiting · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes nausea/vomiting grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review
Cardiac toxicity grade III/IV · adults with acute myeloid leukaemia (AML) (non‐acute promyelocytic leukaemia (APL))
It is very uncertain whether ATRA in addition to chemotherapy changes cardiac toxicity grade III/IV compared with chemotherapy only (very low certainty).
1 finding from 1 review
Time to death from any cause (here: overall mortality at 12‐month
Pembrolizumab probably leads to lower time to death from any cause (here: overall mortality at 12‐month compared with chemotherapy (moderate certainty).
1 finding from 1 review
Quality of life (Change from baseline to week 15)
Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).
1 finding from 1 review
Brain tumour response rates: complete response (CR) and partial response (PR) combinedNo. of participants: 847(6 RCTs)
Pembrolizumab probably leads to higher response rate (partial and complete response) compared with chemotherapy (moderate certainty).
1 finding from 1 review